<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02353299</url>
  </required_header>
  <id_info>
    <org_study_id>PT-D1402</org_study_id>
    <nct_id>NCT02353299</nct_id>
  </id_info>
  <brief_title>Assess the Effect of Zolpidem, Silenor &amp; Placebo on Arousability, Ataxia/Balance &amp; Cognition in Healthy Volunteers</brief_title>
  <official_title>Phase IV 4 Way Crossover Study to Assess and Compare the Effect of a Single Nighttime Administration of Zolpidem, Silenor and Placebo on Arousability, Ataxia/Balance and Cognitive Performance in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pernix Theraputics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Henry Ford Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pernix Theraputics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IV, randomized, double-blind, placebo-controlled, four-arm crossover study.
      The study will assess the effects of a single dose of Silenor 6 mg compared with matching
      placebo and a single dose of zolpidem 10 mg compared to its matching placebo at the
      respective T-max in normal healthy adult male volunteers. The study will be conducted in
      approximately 52 male subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be screened and asked to complete sleep disorders questionnaires and a sleep
      diary to establish normal sleep patterns and to rule out any sleep disorder.

      Eligible subjects will be scheduled for a Screening PSG to rule out PLMS, sleep apnea and
      other sleep disorders.

      Subjects who meet the screening PSG criteria will be randomly assigned to a treatment
      sequence order that involves both the study drug and the time subjects are awakened in the
      middle-of-the-night using a crossover study design. These four sequences include Silenor 6 mg
      with a middle-of-the-night awakening at 4 hours (DXP-4H), zolpidem 10 mg with a
      middle-of-the-night awakening at 1.5 hours (ZOL-1.5H), placebo with a middle-of-the-night
      awakening at 4 hours (PBO-4H), and placebo with a middle-of-the-night awakening at 1.5 hours
      (PBO-1.5H). Study drug will be administered under fasted conditions (at least 4 hours) as a
      single dose at bedtime (approximately 2300 hours), and each subject will receive one dose of
      each active drug (Silenor 6 mg and zolpidem 10 mg), and two doses of placebo during the
      treatment period.

      Safety assessments will be performed throughout the study.

      During the night of assessment, subjects will be awoken at the estimated T-max of the active
      drugs, with a matching placebo group awakened at each of these time points with the same
      arousability protocol. Arousability will be assessed using the Auditory Awakening Threshold
      test (AAT) .

      Once the Auditory Awakening Threshold has been determined, subjects will perform a Tandem
      Walk assessment followed by the Berg Balance Scale (BBS) and finally by Free Recall Memory
      testing.

      Subjects will be discharged from the sleep center once all assessments have been completed. A
      final study visit will be performed for subjects either after they have completed all four
      Treatment Periods or they have prematurely discontinued the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Auditory Arousal Threshold (AAT) at T-max</measure>
    <time_frame>at either 1.5 or 4 hours post dose</time_frame>
    <description>AAT will performed at T-max for Silenor and matching placebo at 4 hours post dose. Assessments performed at t max for zolpidem and placebo at 1.5 hours post dose.
An acoustic stimulus (1000 Hz tone) was presented through audiometric earphones (E-A-RTone 3A Insert Earphones). Tones began at 30 dB and increased by 5 dB until the participant woke up or the maximum dB-level (110 dB) was reached.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tandem Walk Step-Offs</measure>
    <time_frame>at either 1.5 or 4 hours post dose</time_frame>
    <description>Tandem walk will be performed at T-max for Silenor and matching placebo at 4 hours post dose and at 1.5 hours post dose for zolpidem 10 mg and matching placebo.
Fall risk as impacted by balance was measured using the Tandem Walk Test (TWT), which assesses balance via a method of walking in which the toes of the back foot must touch the heel of the front foot at each step; this elicits postural control by reducing the base of support compared to normal walking. Endpoints were the number of step-offs from the beam.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tandem Walk Duration Over Five Trials</measure>
    <time_frame>at either 1.5 or 4 hours post dose</time_frame>
    <description>Tandem walk will be performed at T-max for Silenor and matching placebo at 4 hours post dose and at 1.5 hours post dose for zolpidem 10 mg and matching placebo.
Fall risk as impacted by balance was measured using the Tandem Walk Test (TWT), which assesses balance via a method of walking in which the toes of the back foot must touch the heel of the front foot at each step; this elicits postural control by reducing the base of support compared to normal walking. Endpoint: mean completion duration over five trials.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Berg Balance Test</measure>
    <time_frame>at either 1.5 or 4 hours post dose</time_frame>
    <description>Berg Balance will be performed at T-max for silenor and matching placebo at 4 hours post dose and at 1.5 hours post dose for zolpidem 10 mg and matching placebo.
Fall risk as impacted by gait was measured using the Berg Balance Scale (BBS). The BBS is a widely used clinical test of static and dynamic balance abilities. Comprising of 14 simple balance-related tasks, ranging from standing up from a sitting position to standing on one foot, the BBS takes 15-20 minutes to complete. Each component task is scored on a Likert scale: 0 (unable to perform) to 4 (performed independently). The sum of component scores yields the final BBS score (0-20: high fall risk; 21-40: medium fall risk; 41-56: low fall risk).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immediate Free Recall Task</measure>
    <time_frame>directly after the encoding task</time_frame>
    <description>Immediate Free Recall will be performed at T-max for silenor and matching placebo at 4 hours post dose and at 1.5 hours post dose for zolpidem 10 mg and matching placebo.
Free Recall is a basic paradigm in the psychological study of memory. In this paradigm, participants were presented with a total of 16 words serially. They were informed prior to the task that memory for the presented words would be tested later in the session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed Free Recall Task</measure>
    <time_frame>15 minutes after final awakening the morning</time_frame>
    <description>Delayed Free Recall Task was performed 15 minutes after final awakening the morning
Free Recall is a basic paradigm in the psychological study of memory. In this paradigm, participants were presented with a total of 16 words serially. They were informed prior to the task that memory for the presented words would be tested later in the session. Participants were asked to recall as many words as they can 15 minutes after final awakening in the morning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>throughout the study until the final study visit, up to 6 weeks</time_frame>
    <description>Adverse events were defined by any negative event experienced by a participant during the study (assessed in the morning prior to participants leaving the lab) and included the washout period following each treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Silenor 6 mg (DXP-4H)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Silenor 6 mg single nightime dose- 4 hour post dose arousability and cognitive assessments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (PBO-4H)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo single nightime dose -4 hour post dose arousability and cognitive assessments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zolpidem 10 mg (ZOL-1.5H)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>zolpidem 10 mg single nightime dose - 1.5 hour arousability and cognitive assessments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (PBO-1.5H)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo single nightime dose -1.5 hour arousability and cognitive assessments</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silenor 6 mg</intervention_name>
    <description>Silenor 6 mg single nighttime dose.</description>
    <arm_group_label>Silenor 6 mg (DXP-4H)</arm_group_label>
    <arm_group_label>Placebo (PBO-4H)</arm_group_label>
    <arm_group_label>Zolpidem 10 mg (ZOL-1.5H)</arm_group_label>
    <arm_group_label>Placebo (PBO-1.5H)</arm_group_label>
    <other_name>doxepin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zolpidem 10 mg</intervention_name>
    <description>Zolpidem 10 mg single nighttime dose</description>
    <arm_group_label>Silenor 6 mg (DXP-4H)</arm_group_label>
    <arm_group_label>Placebo (PBO-4H)</arm_group_label>
    <arm_group_label>Zolpidem 10 mg (ZOL-1.5H)</arm_group_label>
    <arm_group_label>Placebo (PBO-1.5H)</arm_group_label>
    <other_name>zolpidem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo single nighttime dose-1.5 hours</description>
    <arm_group_label>Silenor 6 mg (DXP-4H)</arm_group_label>
    <arm_group_label>Placebo (PBO-4H)</arm_group_label>
    <arm_group_label>Zolpidem 10 mg (ZOL-1.5H)</arm_group_label>
    <arm_group_label>Placebo (PBO-1.5H)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo single nighttime dose-4 hours</description>
    <arm_group_label>Silenor 6 mg (DXP-4H)</arm_group_label>
    <arm_group_label>Placebo (PBO-4H)</arm_group_label>
    <arm_group_label>Zolpidem 10 mg (ZOL-1.5H)</arm_group_label>
    <arm_group_label>Placebo (PBO-1.5H)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be in good general health as determined by the investigator;

          -  Have a 3-month history of a normal nightly sleep pattern based on the subject's self
             report ;

          -  A usual time in bed

          -  A regular bedtime between 2200 and 2400 hours

          -  No habitual daytime napping;

          -  Epworth Sleepiness Scale score ≤ 10;

          -  Be able to read, understand, and provide written/dated informed consent before
             enrolling in the study, and must be willing and able to comply with all study
             procedures;

          -  Be able to follow verbal and written instructions provided in English

        Exclusion Criteria:

          -  Have a body mass index (BMI) &gt;35 kg/m2

          -  Have symptoms consistent with the diagnosis of any sleep disorder (e.g., insomnia,
             sleep apnea, narcolepsy, periodic leg movements, or restless leg syndrome);

          -  On screening PSG AHI &gt; 10 or PLMAI &gt;10;

          -  Have a known or suspected diagnosis of Acquired Immune Deficiency Syndrome (AIDS), or
             have tested seropositive for human immunodeficiency virus (HIV) antibody or antigen
             previously;

          -  Have any clinically significant abnormal finding in physical examination, neurological
             assessment, vital signs, elevated body temperature, or clinical laboratory tests, as
             determined by the Investigator;

          -  Have a known exaggerated pharmacological sensitivity, hypersensitivity, or history of
             a clinically significant adverse reaction to zolpidem;

          -  Have a known or exaggerated pharmacological sensitivity, hypersensitivity, or
             intolerance to doxepin HCl, any tricyclic antidepressant, or antihistamine;

          -  Currently taking cimetidine or a monoamine oxidase inhibitor (MAOI);

          -  Current diagnosis of severe urinary retention;

          -  Current diagnosis of untreated glaucoma;

          -  Intends to use any medication including over-the-counter (OTC) medications that would
             interfere with normal sleep architecture (such as systemic steroids, beta-adrenergic
             blockers, amphetamines, modafinil, etc.);

          -  Self-reports use of products containing nicotine of greater than 15 cigarettes daily,
             or cannot avoid products containing nicotine during the normal sleep periods;

          -  Self report consumption of more than five alcoholic beverages on any one day or
             greater than 14 alcoholic beverages weekly over the past week;

          -  Have a history of epilepsy or serious head injury;

          -  Used CYP450 2D6 inducers or inhibitors within 7 days before screening;

          -  Have used prescribed or OTC medications within 30 days of screening (Day 0) or intend
             to use any prescription or OTC medication during the study that may interfere with the
             evaluation of the study drug.

          -  Have used an investigational drug within 30 days or five half lives (whichever is
             longer) before screening, or plans to use an investigational drug during the study or
             have used doxepin or zolpidem previously.

          -  Score of &lt; 40 on the BBS at screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Drake, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Hospital Sleep Disorder Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henry Ford Hospital Sleep Disorders &amp; Research Center</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Davis KL, Charey D, Cuyle JT, Nemeroff C. Neuropsychopharmacology, The Fifth Generation of Progress. 2002; Section 13: 1938-1939</citation>
  </reference>
  <reference>
    <citation>Silenor [prescribing information]. Pernix Pharmaceuticals, Inc., San Diego, CA; March 2010.</citation>
  </reference>
  <reference>
    <citation>Sanofi-Synthelabo. Ambien (zolpidem tartrate) complete prescribing information. 2002.</citation>
  </reference>
  <reference>
    <citation>Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec;14(6):540-5.</citation>
    <PMID>1798888</PMID>
  </reference>
  <results_reference>
    <citation>Hori T, Sugita Y, Koga E, Shirakawa S, Inoue K, Uchida S, Kuwahara H, Kousaka M, Kobayashi T, Tsuji Y, Terashima M, Fukuda K, Fukuda N; Sleep Computing Committee of the Japanese Society of Sleep Research Society. Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen &amp; Kales (1968) standard. Psychiatry Clin Neurosci. 2001 Jun;55(3):305-10.</citation>
    <PMID>11422885</PMID>
  </results_reference>
  <results_reference>
    <citation>Berg Balance Scale (BBS)</citation>
  </results_reference>
  <results_reference>
    <citation>Mintzer MZ, Griffiths RR. Selective effects of zolpidem on human memory functions. J Psychopharmacol. 1999;13(1):18-31.</citation>
    <PMID>10221356</PMID>
  </results_reference>
  <results_reference>
    <citation>Gottlieb DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, Shahar E. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010 Jul 27;122(4):352-60. doi: 10.1161/CIRCULATIONAHA.109.901801. Epub 2010 Jul 12.</citation>
    <PMID>20625114</PMID>
  </results_reference>
  <results_reference>
    <citation>Chung F, Yegneswaran B, Liao P, Chung SA, Vairavanathan S, Islam S, Khajehdehi A, Shapiro CM. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology. 2008 May;108(5):812-21. doi: 10.1097/ALN.0b013e31816d83e4.</citation>
    <PMID>18431116</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2015</study_first_submitted>
  <study_first_submitted_qc>January 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <results_first_submitted>January 30, 2017</results_first_submitted>
  <results_first_submitted_qc>November 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 7, 2017</results_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cognition</keyword>
  <keyword>Balance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
    <mesh_term>Doxepin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PBO-4H Then PBO-1.5H Then DXP-4H Then ZOL-1.5H</title>
          <description>Period 1: Doxepin-matching placebo-single nighttime dose Period 2: Zolpidem-matching placebo-single nighttime dose Period 3: Doxepin 6mg-single nighttime dose Period 4: Zolpidem 10 mg-single nighttime dose</description>
        </group>
        <group group_id="P2">
          <title>PBO-1.5H Then ZOL-1.5H Then PBO-4H Then DXP-4H</title>
          <description>Period 1: Zolpidem-matching placebo-single nighttime dose Period 2: Zolpidem 10 mg-single nighttime dose Period 3: Doxepin-matching placebo-single nighttime dose Period 4: Doxepin 6mg-single nighttime dose</description>
        </group>
        <group group_id="P3">
          <title>ZOL-1.5H Then DXP-4H Then PBO-1.5H Then PBO-4H</title>
          <description>Period 1: Zolpidem 10mg-single nighttime dose Period 2: Doxepin 6mg-single nighttime dose Period 3: Zolpidem-matching placebo-single nighttime dose Period 4: Doxepin-matching placebo-single nighttime dose</description>
        </group>
        <group group_id="P4">
          <title>DXP-4H Then PBO-4H Then ZOL-1.5H Then PBO-1.5H</title>
          <description>Period 1: Doxepin 6mg-single nighttime dose Period 2: Doxepin-matching placebo-single nighttime dose Period 3: Zolpidem 10mg-single nighttime dose Period 4: Zolpidem-matching placebo-single nighttime dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Night)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (1 Night)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention (1 Night)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Fourth Intervention (1 Night)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12">One patient withdrawn from study prior to start of fourth intervention.</participants>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects were healthy males</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>A single group of subjects were recruited and assigned all study treatments in random order</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Auditory Arousal Threshold (AAT) at T-max</title>
        <description>AAT will performed at T-max for Silenor and matching placebo at 4 hours post dose. Assessments performed at t max for zolpidem and placebo at 1.5 hours post dose.
An acoustic stimulus (1000 Hz tone) was presented through audiometric earphones (E-A-RTone 3A Insert Earphones). Tones began at 30 dB and increased by 5 dB until the participant woke up or the maximum dB-level (110 dB) was reached.</description>
        <time_frame>at either 1.5 or 4 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Silenor 6 mg (DXP-4H)</title>
            <description>Silenor 6 mg single nightime dose- 4 hour post dose arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (PBO-4H)</title>
            <description>placebo single nightime dose -4 hour post dose arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 10 mg (ZOL-1.5H)</title>
            <description>zolpidem 10 mg single nightime dose - 1.5 hour arousability and cognitive assessments
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose</description>
          </group>
          <group group_id="O4">
            <title>Placebo (PBO-1.5H)</title>
            <description>placebo single nightime dose -1.5 hour arousability and cognitive assessments
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose</description>
          </group>
        </group_list>
        <measure>
          <title>Auditory Arousal Threshold (AAT) at T-max</title>
          <description>AAT will performed at T-max for Silenor and matching placebo at 4 hours post dose. Assessments performed at t max for zolpidem and placebo at 1.5 hours post dose.
An acoustic stimulus (1000 Hz tone) was presented through audiometric earphones (E-A-RTone 3A Insert Earphones). Tones began at 30 dB and increased by 5 dB until the participant woke up or the maximum dB-level (110 dB) was reached.</description>
          <units>Decibels (dB)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.2" spread="11.8"/>
                    <measurement group_id="O2" value="78.0" spread="18.6"/>
                    <measurement group_id="O3" value="103.2" spread="11.8"/>
                    <measurement group_id="O4" value="84.7" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tandem Walk Step-Offs</title>
        <description>Tandem walk will be performed at T-max for Silenor and matching placebo at 4 hours post dose and at 1.5 hours post dose for zolpidem 10 mg and matching placebo.
Fall risk as impacted by balance was measured using the Tandem Walk Test (TWT), which assesses balance via a method of walking in which the toes of the back foot must touch the heel of the front foot at each step; this elicits postural control by reducing the base of support compared to normal walking. Endpoints were the number of step-offs from the beam.</description>
        <time_frame>at either 1.5 or 4 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO-4H)</title>
            <description>placebo single nightime dose -4 hour post dose arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.</description>
          </group>
          <group group_id="O2">
            <title>Silenor 6 mg (DXP-4H)</title>
            <description>Silenor 6 mg single nightime dose- 4 hour post dose arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 10 mg (ZOL-1.5H)</title>
            <description>zolpidem 10 mg single nightime dose - 1.5 hour arousability and cognitive assessments
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose</description>
          </group>
          <group group_id="O4">
            <title>Placebo (PBO-1.5H)</title>
            <description>placebo single nightime dose -1.5 hour arousability and cognitive assessments
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose</description>
          </group>
        </group_list>
        <measure>
          <title>Tandem Walk Step-Offs</title>
          <description>Tandem walk will be performed at T-max for Silenor and matching placebo at 4 hours post dose and at 1.5 hours post dose for zolpidem 10 mg and matching placebo.
Fall risk as impacted by balance was measured using the Tandem Walk Test (TWT), which assesses balance via a method of walking in which the toes of the back foot must touch the heel of the front foot at each step; this elicits postural control by reducing the base of support compared to normal walking. Endpoints were the number of step-offs from the beam.</description>
          <units>number of step offs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.4"/>
                    <measurement group_id="O2" value="1.5" spread="2.4"/>
                    <measurement group_id="O3" value="8.1" spread="8.0"/>
                    <measurement group_id="O4" value="1.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tandem Walk Duration Over Five Trials</title>
        <description>Tandem walk will be performed at T-max for Silenor and matching placebo at 4 hours post dose and at 1.5 hours post dose for zolpidem 10 mg and matching placebo.
Fall risk as impacted by balance was measured using the Tandem Walk Test (TWT), which assesses balance via a method of walking in which the toes of the back foot must touch the heel of the front foot at each step; this elicits postural control by reducing the base of support compared to normal walking. Endpoint: mean completion duration over five trials.</description>
        <time_frame>at either 1.5 or 4 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO-4H)</title>
            <description>placebo single nightime dose -4 hour post dose arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose
Placebo: placebo single nighttime dose-1.5 hours
Placebo: placebo single nighttime dose-4 hours</description>
          </group>
          <group group_id="O2">
            <title>Silenor 6 mg (DXP-4H)</title>
            <description>Silenor 6 mg single nightime dose- 4 hour post dose arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose
Placebo: placebo single nighttime dose-1.5 hours
Placebo: placebo single nighttime dose-4 hours</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 10 mg (ZOL-1.5H)</title>
            <description>zolpidem 10 mg single nightime dose - 1.5 hour arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose
Placebo: placebo single nighttime dose-1.5 hours
Placebo: placebo single nighttime dose-4 hours</description>
          </group>
          <group group_id="O4">
            <title>Placebo (PBO-1.5H)</title>
            <description>placebo single nightime dose -1.5 hour arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose
Placebo: placebo single nighttime dose-1.5 hours
Placebo: placebo single nighttime dose-4 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Tandem Walk Duration Over Five Trials</title>
          <description>Tandem walk will be performed at T-max for Silenor and matching placebo at 4 hours post dose and at 1.5 hours post dose for zolpidem 10 mg and matching placebo.
Fall risk as impacted by balance was measured using the Tandem Walk Test (TWT), which assesses balance via a method of walking in which the toes of the back foot must touch the heel of the front foot at each step; this elicits postural control by reducing the base of support compared to normal walking. Endpoint: mean completion duration over five trials.</description>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.82" spread="1.68"/>
                    <measurement group_id="O2" value="4.97" spread="1.57"/>
                    <measurement group_id="O3" value="6.69" spread="2.60"/>
                    <measurement group_id="O4" value="4.83" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Berg Balance Test</title>
        <description>Berg Balance will be performed at T-max for silenor and matching placebo at 4 hours post dose and at 1.5 hours post dose for zolpidem 10 mg and matching placebo.
Fall risk as impacted by gait was measured using the Berg Balance Scale (BBS). The BBS is a widely used clinical test of static and dynamic balance abilities. Comprising of 14 simple balance-related tasks, ranging from standing up from a sitting position to standing on one foot, the BBS takes 15–20 minutes to complete. Each component task is scored on a Likert scale: 0 (unable to perform) to 4 (performed independently). The sum of component scores yields the final BBS score (0-20: high fall risk; 21–40: medium fall risk; 41–56: low fall risk).</description>
        <time_frame>at either 1.5 or 4 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Silenor 6 mg (DXP-4H)</title>
            <description>Silenor 6 mg single nightime dose- 4 hour post dose arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (PBO-4H)</title>
            <description>placebo single nightime dose -4 hour post dose arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 10 mg (ZOL-1.5H)</title>
            <description>zolpidem 10 mg single nightime dose - 1.5 hour arousability and cognitive assessments
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose</description>
          </group>
          <group group_id="O4">
            <title>Placebo (PBO-1.5H)</title>
            <description>placebo single nightime dose -1.5 hour arousability and cognitive assessments
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose</description>
          </group>
        </group_list>
        <measure>
          <title>Berg Balance Test</title>
          <description>Berg Balance will be performed at T-max for silenor and matching placebo at 4 hours post dose and at 1.5 hours post dose for zolpidem 10 mg and matching placebo.
Fall risk as impacted by gait was measured using the Berg Balance Scale (BBS). The BBS is a widely used clinical test of static and dynamic balance abilities. Comprising of 14 simple balance-related tasks, ranging from standing up from a sitting position to standing on one foot, the BBS takes 15–20 minutes to complete. Each component task is scored on a Likert scale: 0 (unable to perform) to 4 (performed independently). The sum of component scores yields the final BBS score (0-20: high fall risk; 21–40: medium fall risk; 41–56: low fall risk).</description>
          <units>sum of component scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" spread="1.9"/>
                    <measurement group_id="O2" value="55.1" spread="1.4"/>
                    <measurement group_id="O3" value="51.4" spread="4.3"/>
                    <measurement group_id="O4" value="55.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immediate Free Recall Task</title>
        <description>Immediate Free Recall will be performed at T-max for silenor and matching placebo at 4 hours post dose and at 1.5 hours post dose for zolpidem 10 mg and matching placebo.
Free Recall is a basic paradigm in the psychological study of memory. In this paradigm, participants were presented with a total of 16 words serially. They were informed prior to the task that memory for the presented words would be tested later in the session.</description>
        <time_frame>directly after the encoding task</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Silenor 6 mg (DXP-4H)</title>
            <description>Silenor 6 mg single nightime dose- 4 hour post dose arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (PBO-4H)</title>
            <description>placebo single nightime dose -4 hour post dose arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 10 mg (ZOL-1.5H)</title>
            <description>zolpidem 10 mg single nightime dose - 1.5 hour arousability and cognitive assessments
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose</description>
          </group>
          <group group_id="O4">
            <title>Placebo (PBO-1.5H)</title>
            <description>placebo single nightime dose -1.5 hour arousability and cognitive assessments
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose</description>
          </group>
        </group_list>
        <measure>
          <title>Immediate Free Recall Task</title>
          <description>Immediate Free Recall will be performed at T-max for silenor and matching placebo at 4 hours post dose and at 1.5 hours post dose for zolpidem 10 mg and matching placebo.
Free Recall is a basic paradigm in the psychological study of memory. In this paradigm, participants were presented with a total of 16 words serially. They were informed prior to the task that memory for the presented words would be tested later in the session.</description>
          <units>Number of words</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.86" spread="3.20"/>
                    <measurement group_id="O2" value="8.14" spread="2.99"/>
                    <measurement group_id="O3" value="4.78" spread="3.42"/>
                    <measurement group_id="O4" value="7.71" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delayed Free Recall Task</title>
        <description>Delayed Free Recall Task was performed 15 minutes after final awakening the morning
Free Recall is a basic paradigm in the psychological study of memory. In this paradigm, participants were presented with a total of 16 words serially. They were informed prior to the task that memory for the presented words would be tested later in the session. Participants were asked to recall as many words as they can 15 minutes after final awakening in the morning</description>
        <time_frame>15 minutes after final awakening the morning</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Silenor 6 mg (DXP-4H)</title>
            <description>Silenor 6 mg single nightime dose- 4 hour post dose arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose
Placebo: placebo single nighttime dose-1.5 hours
Placebo: placebo single nighttime dose-4 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo (PBO-4H)</title>
            <description>placebo single nightime dose -4 hour post dose arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose
Placebo: placebo single nighttime dose-1.5 hours
Placebo: placebo single nighttime dose-4 hours</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 10 mg (ZOL-1.5H)</title>
            <description>zolpidem 10 mg single nightime dose - 1.5 hour arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose
Placebo: placebo single nighttime dose-1.5 hours
Placebo: placebo single nighttime dose-4 hours</description>
          </group>
          <group group_id="O4">
            <title>Placebo (PBO-1.5H)</title>
            <description>placebo single nightime dose -1.5 hour arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose
Placebo: placebo single nighttime dose-1.5 hours
Placebo: placebo single nighttime dose-4 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Delayed Free Recall Task</title>
          <description>Delayed Free Recall Task was performed 15 minutes after final awakening the morning
Free Recall is a basic paradigm in the psychological study of memory. In this paradigm, participants were presented with a total of 16 words serially. They were informed prior to the task that memory for the presented words would be tested later in the session. Participants were asked to recall as many words as they can 15 minutes after final awakening in the morning</description>
          <units>Number of words</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.78" spread="3.68"/>
                    <measurement group_id="O2" value="7.02" spread="3.59"/>
                    <measurement group_id="O3" value="2.24" spread="2.77"/>
                    <measurement group_id="O4" value="6.51" spread="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Adverse events were defined by any negative event experienced by a participant during the study (assessed in the morning prior to participants leaving the lab) and included the washout period following each treatment.</description>
        <time_frame>throughout the study until the final study visit, up to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Silenor 6 mg (DXP-4H)</title>
            <description>Silenor 6 mg single nightime dose- 4 hour post dose arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (PBO-4H)</title>
            <description>placebo single nightime dose -4 hour post dose arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 10 mg (ZOL-1.5H)</title>
            <description>zolpidem 10 mg single nightime dose - 1.5 hour arousability and cognitive assessments
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose</description>
          </group>
          <group group_id="O4">
            <title>Placebo (PBO-1.5H)</title>
            <description>placebo single nightime dose -1.5 hour arousability and cognitive assessments
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Adverse events were defined by any negative event experienced by a participant during the study (assessed in the morning prior to participants leaving the lab) and included the washout period following each treatment.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study period until the final study visit, up to 6 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Silenor 6 mg (DXP-4H)</title>
          <description>Silenor 6 mg single nightime dose- 4 hour post dose arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.</description>
        </group>
        <group group_id="E2">
          <title>Placebo (PBO-4H)</title>
          <description>placebo single nightime dose -4 hour post dose arousability and cognitive assessments
Silenor 6 mg: Silenor 6 mg single nighttime dose.</description>
        </group>
        <group group_id="E3">
          <title>Zolpidem 10 mg (ZOL-1.5H)</title>
          <description>zolpidem 10 mg single nightime dose - 1.5 hour arousability and cognitive assessments
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose</description>
        </group>
        <group group_id="E4">
          <title>Placebo (PBO-1.5H)</title>
          <description>placebo single nightime dose -1.5 hour arousability and cognitive assessments
zolpidem 10 mg: Zolpidem 10 mg single nighttime dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (7.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Xerostomia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue/lethargy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher L Drake</name_or_title>
      <organization>Sleep Disorders and Research Center Henry Ford Hospital</organization>
      <phone>248-344-6672</phone>
      <email>cdrake1@hfhs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

